Cancer Commons Featured in SF Business Times

Trial and error: Biotechs, patients, FDA search for faster, cheaper ways to develop drugs.

From the article by Ron Leuty:

“Take Marty Tenenbaum, a metastatic melanoma survivor who has led efforts to link patients, researchers and companies in an open-science initiative, called Cancer Commons. His thinking is the more that patients know clinical trial results — and, importantly, report their own — the faster patients will populate the right clinical trials that are right for them.”

Read more here.